Last reviewed · How we verify
WCK-2349
At a glance
| Generic name | WCK-2349 |
|---|---|
| Sponsor | Wockhardt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349 (PHASE1)
- Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers (PHASE1)
- Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment (PHASE1)
- Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects (PHASE1)
- Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WCK-2349 CI brief — competitive landscape report
- WCK-2349 updates RSS · CI watch RSS
- Wockhardt portfolio CI